Veronique Leblond

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 195 publications

Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group.

Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group.

Journal: EClinicalMedicine

Published: July 30, 2025

Waldenström's macroglobulinemia: The LYSA pragmatic guidelines.

Waldenström's macroglobulinemia: The LYSA pragmatic guidelines.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 28, 2025

Late toxicity and long-term efficacy of first-line bendamustine and rituximab combination in patients with Waldenström macroglobulinemia.

Late toxicity and long-term efficacy of first-line bendamustine and rituximab combination in patients with Waldenström macroglobulinemia.

Journal: Leukemia

Published: June 03, 2025

Phenotypic Profile of Waldenström Macroglobulinaemia B-Cells: Establishment of a Diagnosis Scoring System and Clinico-Biological Correlations.

Phenotypic Profile of Waldenström Macroglobulinaemia B-Cells: Establishment of a Diagnosis Scoring System and Clinico-Biological Correlations.

Journal: Journal of cellular and molecular medicine

Published: October 14, 2024

Expert Opinion on Managing Adverse Reactions Associated With Acalabrutinib Therapy: A Delphi Consensus From France.

Expert Opinion on Managing Adverse Reactions Associated With Acalabrutinib Therapy: A Delphi Consensus From France.

Journal: Clinical lymphoma, myeloma & leukemia

Published: October 02, 2024

Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström's macroglobulinemia.

Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström's macroglobulinemia.

Journal: Annals of hematology

Published: August 26, 2024

Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia.

Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia.

Journal: Blood advances

Published: August 12, 2024

Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial.

Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial.

Journal: Future oncology (London, England)

Published: July 29, 2024

Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.

Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.

Journal: Bone marrow transplantation

Published: June 07, 2024

Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study).

Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study).

Journal: British journal of haematology

Published: February 11, 2024

Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study.

Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study.

Journal: Annals of hematology

Published: December 26, 2023

Long-term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO).

Long-term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO).

Journal: British journal of haematology

Published: December 04, 2023

Showing 1-12 of 195

Last Updated: 09/26/2026